

## Supporting Information

### Ruthenium(II)-Catalyzed C–H Functionalizations of Benzoic Acids with Aryl, Alkenyl and Alkynyl Halides by Weak-*O*-Coordination

Ruhuai Mei,<sup>†</sup> Cuiju Zhu,<sup>†</sup> and Lutz Ackermann\*

<sup>†</sup> *Both authors contributed equally.*

Institut für Organische und Biomolekulare Chemie, Georg-August-Universität

Tammannstraße 2, 37077 Göttingen, Germany

Fax: +49/ 551-39-6777


Lutz.Ackermann@chemie.uni-goettingen.de

General Remarks	S-1
Optimization studies	S-2
General Procedures for the Ruthenium(II)-Catalyzed C–H Arylation and Alkynylation	S-3
Characterization Data of Products <b>3</b> , <b>9</b> and <b>11</b>	S-4
Ruthenium(II)-Catalyzed C–H Alkenylation	S-24
H-D Exchange Experiments	S-25
Competition Experiments	S-28
Ruthenacycle <b>7</b> for C–H Arylation	S-31
References	S-32
NMR Spectra	S-33

## General Remarks

Catalytic reactions were carried out in Schlenk tubes under a nitrogen atmosphere using pre-dried glassware. *N*-Methyl-2-pyrrolidone (NMP) was dried and distilled over CaH<sub>2</sub>. The following starting materials were synthesized according to previously described procedures: [Ru(O<sub>2</sub>CMe)<sub>2</sub>(*p*-cymene)],<sup>[1]</sup> [RuCl<sub>2</sub>(*p*-cymene)(PCy<sub>3</sub>)],<sup>[2]</sup> [RuCl<sub>2</sub>(*p*-cymene)(Ph*t*BuPOH)],<sup>[3]</sup> [RuCl<sub>2</sub>(*p*-cymene)(*n*Bu<sub>2</sub>POH)]<sup>[3]</sup> and ruthenacycle **7**.<sup>[4]</sup> Other chemicals were obtained from commercial sources and were used without further purification. Yields refer to isolated compounds, estimated to be > 95% pure as determined by <sup>1</sup>H-NMR and GC-analysis. Chromatography: Merck silica gel 60 (40-63 μm). NMR: Spectra were recorded on Varian Unity 300, Mercury 300 or Inova 500 in the solvent indicated; chemical shifts (δ) are given in ppm. All IR spectra were recorded on a Bruker FT-IR Alpha device. MS: EI-MS- and ESI-MS-spectra were recorded with Finnigan MAT 95, 70 eV; High resolution mass spectrometry (HRMS) with APEX IV 7T FTICR, Bruker Daltonic. M. p.: Stuart melting point apparatus SMP3, Barloworld Scientific, values are uncorrected.

**Table S-1 Optimization Study for Ruthenium (II)-Catalyzed C–H Arylation<sup>a</sup>**



entry	[Ru]	ligand	<b>3aa</b> (%) <sup>b</sup>
1	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	---	(11)
2	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	IPrHCl	(<5)
3	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	IMesHCl	(<5)
4	[Ru(O <sub>2</sub> CMes) <sub>2</sub> ( <i>p</i> -cymene)]	X-Phos	(7)
5	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	DavePhos	(<5)
6	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	JohnPhos	(8)
7	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	<i>t</i> Bu <sub>2</sub> POH	16
8	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	Cy <sub>2</sub> POH	(<5)
9	[RuCl <sub>2</sub> ( <i>p</i> -cymene)(Ph <i>t</i> BuPOH)]	---	(<5)
10	[RuCl <sub>2</sub> ( <i>p</i> -cymene)( <i>n</i> Bu <sub>2</sub> POH)]	---	(6)
11	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	P( <i>n</i> Bu)(Adamantyl) <sub>2</sub>	20
12	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	PPh <sub>3</sub>	(51)
13	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	P <sup><i>t</i></sup> Bu <sub>3</sub>	(22)
14	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	PCy <sub>3</sub>	81
15 <sup>c</sup>	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	PCy <sub>3</sub>	n.d.
16	---	PCy <sub>3</sub>	n.d.
17 <sup>d</sup>	[RuCl <sub>2</sub> ( <i>p</i> -cymene)] <sub>2</sub>	PCy <sub>3</sub>	(5)
<b>18</b>	<b>[Ru(O<sub>2</sub>CMes)<sub>2</sub>(<i>p</i>-cymene)] (4)</b>	<b>PCy<sub>3</sub></b>	<b>87</b>
19	[RuCl <sub>2</sub> ( <i>p</i> -cymene)(PCy <sub>3</sub> )]	---	75
20 <sup>e</sup>	[Ru(O <sub>2</sub> CMes) <sub>2</sub> ( <i>p</i> -cymene)] (4)	PCy <sub>3</sub>	54
21 <sup>f</sup>	[Ru(O <sub>2</sub> CMes) <sub>2</sub> ( <i>p</i> -cymene)] (4)	PCy <sub>3</sub>	n.d.
22 <sup>g</sup>	[Ru(O <sub>2</sub> CMes) <sub>2</sub> ( <i>p</i> -cymene)] (4)	PCy <sub>3</sub>	(32)

<sup>a</sup> Reaction conditions: **1a** (0.50 mmol), **2a** (0.75 mmol), [Ru] (10 mol %), ligand (10 mol %), K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), and NMP (2.0 mL), 120 °C, 16 h; then K<sub>2</sub>CO<sub>3</sub> (3.0 equiv) and MeI (5.0 equiv) in MeCN (3.0 mL). <sup>b</sup> Yields of isolated product; in parentheses: GC conversion with 1,3,5-trimethoxybenzene as the internal standard. <sup>c</sup> Without K<sub>2</sub>CO<sub>3</sub>. <sup>d</sup> Using 4-chloroanisole instead of 4-bromoanisole. <sup>e</sup> DMA (2.0 mL) as solvent. <sup>f</sup> PhMe (2.0 mL) as solvent. <sup>g</sup> DMPU (2.0 mL) as solvent.

## General Procedures for the Ruthenium (II)-Catalyzed C–H Arylation and Alkynylation


### General Procedure for the C–H Arylations of Benzoic Acids (GP1)

A suspension of [Ru(O<sub>2</sub>CMes)<sub>2</sub>(*p*-cymene)] (**4**) (28.1 mg, 10 mol %), PCy<sub>3</sub> (14.0 mg, 10 mol %), K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.00 mmol), benzoic acid **1** (0.50 mmol), and aryl halide **2** (0.75 mmol, 1.50 equiv) in NMP (2.0 mL) was stirred under N<sub>2</sub> for 16 h at 120 °C. At ambient temperature, MeCN (3.0 mL), K<sub>2</sub>CO<sub>3</sub> (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 °C for another 2 h. At ambient temperature, the mixture was diluted with MTBE (120 mL), then washed with H<sub>2</sub>O (20 mL) and brine (20 mL) sequentially. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc) to yield the ester **3**.

### General Procedure for the C–H Alkynylation of Benzoic Acids (GP2)

A suspension of [Ru(O<sub>2</sub>CMes)<sub>2</sub>(*p*-cymene)] (**4**) (28.1 mg, 10 mol %), PCy<sub>3</sub> (14.0 mg, 10 mol %), K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.00 mmol), benzoic acid **1** (0.50 mmol), and (bromoethynyl)triisopropylsilane (**10a**) (195 mg, 0.75 mmol) in NMP (2.0 mL) was stirred under N<sub>2</sub> for 16 h at 120 °C. At ambient temperature, the mixture was diluted with MTBE (120 mL), then washed with H<sub>2</sub>O (20 mL) and brine (20 mL) sequentially. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc) to yield ester **11**.


## Characterization Data of Products 3, 9 and 11



### Methyl 4'-methoxy-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3aa**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2a** (140 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3aa** (111 mg, 87%) as a white solid. M. p. = 69–70 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.35–7.25 (m, 3H), 7.21–7.14 (m, 2H), 6.91 (d, *J* = 8.7 Hz, 2H), 3.82 (s, 3H), 3.61 (s, 3H), 2.37 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  = 170.5 (C<sub>q</sub>), 159.0 (C<sub>q</sub>), 139.6 (C<sub>q</sub>), 135.3 (C<sub>q</sub>), 133.3 (C<sub>q</sub>), 133.2 (C<sub>q</sub>), 129.3 (CH), 129.3 (CH), 128.7 (CH), 127.2 (CH), 113.7 (CH), 55.2 (CH<sub>3</sub>), 51.8 (CH<sub>3</sub>), 19.7 (CH<sub>3</sub>). IR (ATR): 2946, 2837, 1724, 1510, 1245, 1028, 791 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 256 (100) [M<sup>+</sup>], 225 (90), 209 (30), 197 (15), 182 (30), 153 (40). HR-MS (EI) *m/z* calcd for C<sub>16</sub>H<sub>16</sub>O<sub>3</sub> [M<sup>+</sup>] 256.1099, found 256.1109.

The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>




### Methyl 3,4'-dimethyl-[1,1'-biphenyl]-2-carboxylate (**3ab**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2b** (128 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ab** (104 mg, 87%) as a pale yellow oil. <sup>1</sup>H NMR (400

MHz, CDCl<sub>3</sub>)  $\delta$  = 7.36 (dd,  $J$  = 7.6, 7.6 Hz, 1H), 7.27 (d,  $J$  = 8.1 Hz, 2H), 7.24–7.19 (m, 4H), 3.64 (s, 3H), 2.42 (s, 3H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  = 170.5 (C<sub>q</sub>), 140.2 (C<sub>q</sub>), 138.1 (C<sub>q</sub>), 137.1 (C<sub>q</sub>), 135.4 (C<sub>q</sub>), 133.3 (C<sub>q</sub>), 129.5 (CH), 129.1 (CH), 129.0 (CH), 128.2 (CH), 127.3 (CH), 51.9 (CH<sub>3</sub>), 21.3 (CH<sub>3</sub>), 19.8 (CH<sub>3</sub>). IR (ATR): 3025, 1724, 1459, 1435, 1264, 1120, 1066, 823, 784, 529 cm<sup>-1</sup>. MS (EI)  $m/z$  (relative intensity): 240 (70) [M<sup>+</sup>], 209 (100), 224 (100), 165 (68), 152 (12). HR-MS (EI):  $m/z$  calcd for C<sub>16</sub>H<sub>16</sub>O<sub>2</sub> [M<sup>+</sup>] 240.1150, found 240.1139.


The analytical data are in accordance with those previously reported in the literature.<sup>[5,6]</sup>



### Methyl 4'-(*tert*-butyl)-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3ac**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2c** (160 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ac** (121 mg, 86%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.41 (d,  $J$  = 8.4 Hz, 2H), 7.33 (dd,  $J$  = 8.0, 8.0 Hz, 1H), 7.30 (d,  $J$  = 8.4 Hz, 2H), 7.27–7.16 (m, 2H), 3.61 (s, 3H), 2.42 (s, 3H), 1.37 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  = 170.6 (C<sub>q</sub>), 150.3 (C<sub>q</sub>), 140.2 (C<sub>q</sub>), 138.0 (C<sub>q</sub>), 135.4 (C<sub>q</sub>), 133.3 (C<sub>q</sub>), 129.5 (CH), 129.0 (CH), 128.0 (CH), 127.4 (CH), 125.3 (CH), 51.9 (CH<sub>3</sub>), 34.7 (C<sub>q</sub>), 31.5 (CH<sub>3</sub>), 19.8 (CH<sub>3</sub>). IR (ATR): 2960, 1726, 1461, 1267, 1085, 959, 839, 789, 750, 586 cm<sup>-1</sup>. MS (EI)  $m/z$  (relative intensity): 282 (33) [M<sup>+</sup>], 267 (100), 207 (14), 193 (15), 165 (12); HR-MS (EI):  $m/z$  calcd for C<sub>19</sub>H<sub>22</sub>O<sub>2</sub> [M<sup>+</sup>] 282.1620, found 282.1621.


The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>



### Methyl 4'-fluoro-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3ad**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2d** (131 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ad** (96 mg, 79%) as a pale yellow solid. M. p. = 68–69 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.40–7.30 (m, 3H), 7.24–7.17 (m, 2H), 7.08 (dd, *J* = 8.8, 8.8 Hz, 2H), 3.61 (s, 3H), 2.40 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 170.3 (C<sub>q</sub>), 162.3 (d, <sup>1</sup>*J*<sub>C-F</sub> = 243.6 Hz, C<sub>q</sub>), 139.2 (C<sub>q</sub>), 137.0 (d, <sup>4</sup>*J*<sub>C-F</sub> = 3.3 Hz, C<sub>q</sub>), 135.6 (C<sub>q</sub>), 133.4 (C<sub>q</sub>), 130.0 (d, <sup>3</sup>*J*<sub>C-F</sub> = 8.1 Hz, CH), 129.3 (d, <sup>2</sup>*J*<sub>C-F</sub> = 19.6 Hz, CH), 127.3 (CH), 115.4 (CH), 115.2 (CH), 52.0 (CH<sub>3</sub>), 19.8 (CH<sub>3</sub>). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ = -115.19 (tt, *J* = 8.5, 5.3 Hz). IR (ATR): 2949, 1735, 1600, 1508, 1434, 1262, 843, 741 cm<sup>-1</sup>. MS (ESI) *m/z* (relative intensity): 245 (4) [M+H<sup>+</sup>] 267 (100) [M+Na<sup>+</sup>]. HR-MS (ESI): *m/z* calcd for C<sub>15</sub>H<sub>14</sub>FO<sub>2</sub> [M+H<sup>+</sup>] 245.0972, found 245.0971.


The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>



### Methyl 3-methyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylate (**3ae**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2e** (169 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ae** (118 mg, 80%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 7.65 (dd, *J* = 8.0, 8.0 Hz, 2H), 7.48 (dd, *J* = 8.0, 8.0 Hz, 2H), 7.39 (dd, *J* = 7.7, 7.7 Hz, 1H), 7.27–7.24 (m, 1H), 7.20–7.17 (m, 1H), 3.60 (s, 3H), 2.42 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ = 170.0 (C<sub>q</sub>), 144.7 (d, <sup>5</sup>*J*<sub>C-F</sub> = 1.4 Hz, C<sub>q</sub>), 138.9 (C<sub>q</sub>), 136.0 (C<sub>q</sub>), 133.2 (C<sub>q</sub>), 130.1 (CH), 129.5 (q, <sup>2</sup>*J*<sub>C-F</sub> = 33.2 Hz, C<sub>q</sub>), 129.8 (CH), 128.8 (CH), 127.2 (CH), 125.4


(q,  $^3J_{\text{C-F}} = 3.8$  Hz, CH), 124.2 (q,  $^1J_{\text{C-F}} = 269.5$  Hz, C<sub>q</sub>), 52.1 (CH<sub>3</sub>), 19.9 (CH<sub>3</sub>).  $^{19}\text{F}$  NMR (376 MHz, CDCl<sub>3</sub>)  $\delta = -62.48$  (s). IR (ATR): 2953, 1727, 1619, 1438, 1324, 1264, 1120, 847, 790, 584 cm<sup>-1</sup>. MS (EI)  $m/z$  (relative intensity): 294 (45) [M<sup>+</sup>], 263 (100), 215 (20), 165 (48), 43 (22). HR-MS (EI):  $m/z$  calcd for C<sub>16</sub>H<sub>13</sub>F<sub>3</sub>O<sub>2</sub> [M<sup>+</sup>] 294.0868, found 294.0879.



### Dimethyl 3-methyl-[1,1'-biphenyl]-2,4'-dicarboxylate (**3af**)


The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2f** (161 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 15:1) yielded **3af** (109 mg, 77%) as a yellow oil.  $^1\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta = 8.04$  (d,  $J = 8.6$  Hz, 2H), 7.40 (d,  $J = 8.6$  Hz, 2H), 7.37 (dd,  $J = 7.6, 7.6$  Hz, 1H), 7.26–7.19 (m, 2H), 3.93 (s, 3H), 3.57 (s, 3H), 2.41 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz, CDCl<sub>3</sub>)  $\delta = 169.8$  (C<sub>q</sub>), 166.8 (C<sub>q</sub>), 145.7 (C<sub>q</sub>), 139.2 (C<sub>q</sub>), 135.9 (C<sub>q</sub>), 133.0 (C<sub>q</sub>), 129.8 (CH), 129.6 (CH), 129.6 (CH), 129.1 (C<sub>q</sub>), 128.3 (CH), 127.1 (CH), 52.2 (CH<sub>3</sub>), 52.0 (CH<sub>3</sub>), 19.9 (CH<sub>3</sub>). IR (ATR): 2949, 1712, 1610, 1434, 1264, 1114, 1066, 862, 704 cm<sup>-1</sup>. MS (EI)  $m/z$  (relative intensity): 284 (96) [M<sup>+</sup>], 253 (100), 209 (60), 165 (85), 152 (18). HR-MS (EI):  $m/z$  calcd for C<sub>17</sub>H<sub>16</sub>O<sub>4</sub> [M<sup>+</sup>] 284.1049, found 284.1040.

The analytical data are in accordance with those previously reported in the literature.<sup>[51]</sup>



#### 4'-Ethyl 2-methyl 3-methyl-[1,1'-biphenyl]-2,4'-dicarboxylate (**3ag**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2g** (172 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ag** (134 mg, 90%) as a colorless oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  = 8.05 (d,  $J$  = 8.3 Hz, 2H), 7.40 (d,  $J$  = 8.3 Hz, 2H), 7.36–7.31 (m, 1H), 7.26–7.12 (m, 2H), 4.36 (q,  $J$  = 7.1 Hz, 2H), 3.55 (s, 3H), 2.38 (s, 3H), 1.37 (t,  $J$  = 7.1 Hz, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  = 169.8 ( $\text{C}_q$ ), 166.3 ( $\text{C}_q$ ), 145.4 ( $\text{C}_q$ ), 139.1 ( $\text{C}_q$ ), 135.7 ( $\text{C}_q$ ), 132.9 ( $\text{C}_q$ ), 129.7 (CH), 129.4 (CH), 129.4 ( $\text{C}_q$ ), 129.3 (CH), 128.1 (CH), 126.9 (CH), 60.9 ( $\text{CH}_2$ ), 51.8 ( $\text{CH}_3$ ), 19.6 ( $\text{CH}_3$ ), 14.2 ( $\text{CH}_3$ ). IR (ATR): 2981, 2950, 1712, 1610, 1460, 1366, 1100, 766  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity) 298 (100) [ $\text{M}^+$ ], 267 (30), 253 (80), 239 (20), 225 (20), 195 (80), 165 (60). HR-MS (EI)  $m/z$  calcd for  $\text{C}_{18}\text{H}_{18}\text{O}_4$  [ $\text{M}^+$ ] 298.1205, found 298.1210.




#### Methyl 4'-acetyl-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3ah**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2h** (149 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 15:1) yielded **3ah** (114 mg, 85%) as a yellow solid. M. p. = 132–133 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.95 (d,  $J$  = 8.4 Hz, 2H), 7.42 (d,  $J$  = 8.4 Hz, 2H), 7.35 (dd,  $J$  = 7.6, 7.6 Hz, 1H), 7.25–7.17 (m, 2H), 3.58 (s, 3H), 2.60 (s, 3H), 2.39 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  = 197.7 ( $\text{C}_q$ ), 170.0 ( $\text{C}_q$ ), 145.8 ( $\text{C}_q$ ), 139.1 ( $\text{C}_q$ ), 136.0 ( $\text{C}_q$ ), 135.9 ( $\text{C}_q$ ), 133.0 ( $\text{C}_q$ ), 129.9 (CH), 129.6 (CH), 128.5 (CH), 128.4 (CH), 127.1 (CH), 52.0 ( $\text{CH}_3$ ), 26.7 ( $\text{CH}_3$ ), 19.8 ( $\text{CH}_3$ ). IR (ATR): 2949, 1718, 1680, 1605, 1434, 1268, 1061, 845,


795, 601  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity): 268 (45)  $[\text{M}]^+$ , 253 (100), 195 (35), 165 (37), 43 (28). HR-MS (ESI):  $m/z$  calcd for  $\text{C}_{17}\text{H}_{17}\text{O}_3$   $[\text{M}+\text{H}^+]$  269.1172, found 269.1172.

The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>



### Methyl 3-methyl-3'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylate (**3ai**)


The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2i** (169 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ai** (115 mg, 78%) as a colorless oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.66–7.44 (m, 4H), 7.37 (dd,  $J$  = 7.6, 7.6 Hz, 1H), 7.28–7.18 (m, 2H), 3.60 (s, 3H), 2.40 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  = 169.8 ( $\text{C}_q$ ), 141.6 ( $\text{C}_q$ ), 138.6 ( $\text{C}_q$ ), 135.8 ( $\text{C}_q$ ), 133.2 ( $\text{C}_q$ ), 131.6 (q,  $^4J_{\text{C-F}}$  = 1.3 Hz, CH), 130.7 (q,  $^2J_{\text{C-F}}$  = 32.2 Hz,  $\text{C}_q$ ), 129.8 (CH), 129.6 (CH), 128.8 (CH), 127.1 (CH), 125.0 (q,  $^3J_{\text{C-F}}$  = 3.8 Hz, CH), 124.1 (q,  $^3J_{\text{C-F}}$  = 3.8 Hz, CH), 124.0 (q,  $^1J_{\text{C-F}}$  = 272.3 Hz,  $\text{C}_q$ ), 124.0, 51.8 ( $\text{CH}_3$ ), 19.7 ( $\text{CH}_3$ ).  $^{19}\text{F}$  NMR (283 MHz,  $\text{CDCl}_3$ )  $\delta$  = -62.6 (s). IR (ATR): 2949, 1729, 1483, 1334, 1118, 1065, 703  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity) 294 (40)  $[\text{M}^+]$ , 263 (100), 243 (5), 235 (10), 215 (20), 193 (5), 165 (40). HR-MS (EI)  $m/z$  calcd for  $\text{C}_{16}\text{H}_{13}\text{F}_3\text{O}_2$   $[\text{M}^+]$  294.0868, found 294.0866.



### Methyl 3'-methoxy-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3aj**)


The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2j** (140 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica

gel (*n*-hexane/EtOAc 20:1) yielded **3aj** (92.2 mg, 72%) as a pale yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.40–7.27 (m, 2H), 7.26–7.19 (m, 2H), 7.03–6.80 (m, 3H), 3.83 (s, 3H), 3.63 (s, 3H), 2.41 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 170.2 (C<sub>q</sub>), 159.5 (C<sub>q</sub>), 142.3 (C<sub>q</sub>), 140.0 (C<sub>q</sub>), 135.4 (C<sub>q</sub>), 133.2 (C<sub>q</sub>), 129.4 (CH), 129.3 (CH), 129.2 (CH), 127.2 (CH), 120.8 (CH), 113.7 (CH), 113.4 (CH), 55.4 (CH<sub>3</sub>), 52.0 (CH<sub>3</sub>), 19.9 (CH<sub>3</sub>). IR (ATR): 2999, 2835, 1724, 1489, 1318, 1228, 1066, 1040, 776, 698 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity): 256 (67) [M<sup>+</sup>], 225 (78), 224 (100), 182 (27), 153 (28). HR-MS (EI): *m/z* calcd for C<sub>16</sub>H<sub>16</sub>O<sub>3</sub> [M<sup>+</sup>] 256.1099, found 256.1090.




### Methyl 3'-acetyl-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3ak**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2k** (149 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 15:1) yielded **3ak** (103 mg, 77%) as a pale yellow solid. M. p. = 63–64 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.00–7.88 (m, 2H), 7.57–7.54 (m, 1H), 7.47 (dd, *J* = 7.6, 7.6 Hz, 1H), 7.36 (dd, *J* = 7.6, 7.6 Hz, 1H), 7.25–7.20 (m, 2H), 3.59 (s, 3H), 2.60 (s, 3H), 2.40 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 197.9 (C<sub>q</sub>), 170.1 (C<sub>q</sub>), 141.3 (C<sub>q</sub>), 139.1 (C<sub>q</sub>), 137.2 (C<sub>q</sub>), 135.7 (C<sub>q</sub>), 133.3 (C<sub>q</sub>), 132.8 (CH), 129.7 (CH), 129.6 (CH), 128.7 (CH), 128.3 (CH), 127.3 (CH), 127.2 (CH), 51.9 (CH<sub>3</sub>), 26.7 (CH<sub>3</sub>), 19.8 (CH<sub>3</sub>). IR (ATR): 2950, 1725, 1600, 1357, 1238, 1066, 956, 808, 732 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity): 268 (45) [M<sup>+</sup>], 253 (85), 236 (100), 221 (70), 195 (65). HR-MS (EI): *m/z* calcd for C<sub>17</sub>H<sub>16</sub>O<sub>3</sub> [M<sup>+</sup>] 268.1099, found 268.1096.



### Methyl 3',5'-difluoro-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3al**)


The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2l** (145 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3al** (110 mg, 84%) as a colorless solid. M. p. = 63–64 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.37 (dd, *J* = 7.6, 7.6 Hz, 1H), 7.26 (d, *J* = 7.6 Hz, 1H), 7.17 (d, *J* = 7.6 Hz, 1H), 6.96–6.85 (m, 2H), 6.83–6.75 (m, 1H), 3.67 (s, 3H), 2.40 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 169.6 (C<sub>q</sub>), 162.7 (dd, <sup>1,3</sup>*J*<sub>C-F</sub> = 248.7, 13.0 Hz, C<sub>q</sub>), 144.1 (t, <sup>3,3</sup>*J*<sub>C-F</sub> = 25.3 Hz, C<sub>q</sub>), 137.8 (t, <sup>4,4</sup>*J*<sub>C-F</sub> = 2.4 Hz, C<sub>q</sub>), 135.8 (C<sub>q</sub>), 132.9 (C<sub>q</sub>), 130.1 (CH), 129.6 (CH), 126.8 (CH), 111.3 (dd, <sup>2,4</sup>*J*<sub>C-F</sub> = 17.3, 8.1 Hz, CH), 102.8 (t, <sup>2,2</sup>*J*<sub>C-F</sub> = 25.3 Hz, CH), 52.0 (CH<sub>3</sub>), 19.7 (CH<sub>3</sub>). <sup>19</sup>F NMR (283 MHz, CDCl<sub>3</sub>) δ = -(109.8–109.9) (m). IR (ATR): 2951, 1726, 1622, 1454, 1337, 1117, 793 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 262 (60) [M<sup>+</sup>], 231 (100), 253 (80), 201 (60), 188 (30), 183 (50), 151 (50). HR-MS (ESI) *m/z* calcd for C<sub>15</sub>H<sub>13</sub>F<sub>2</sub>O<sub>2</sub> [M+H<sup>+</sup>] 263.0878, found 263.0875.



### Methyl (*E*)-4'-(3-methoxy-3-oxoprop-1-en-1-yl)-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3am**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2m** (181 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3am** (126 mg, 81%) as a colorless solid. M. p. = 91–92 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.71 (d, *J* = 16.0 Hz, 1H), 7.55 (d, *J* = 8.5 Hz, 2H),


7.41–7.31 (m, 3H), 7.28–7.18 (m, 2H), 6.47 (d,  $J = 16.0$  Hz, 1H), 3.81 (s, 3H), 3.60 (s, 3H), 2.40 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta = 169.9$  ( $\text{C}_q$ ), 167.2 ( $\text{C}_q$ ), 144.2 (CH), 142.9 ( $\text{C}_q$ ), 139.1 ( $\text{C}_q$ ), 135.6 ( $\text{C}_q$ ), 133.3 ( $\text{C}_q$ ), 132.9 ( $\text{C}_q$ ), 129.5 (CH), 129.4 (CH), 128.7 (CH), 128.0 (CH), 126.9 (CH), 117.8 (CH), 51.8 ( $\text{CH}_3$ ), 51.6 ( $\text{CH}_3$ ), 19.6 ( $\text{CH}_3$ ). IR (ATR): 2944, 1729, 1708, 1604, 1436, 1270, 1170, 790  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity) 310 (80) [ $\text{M}^+$ ], 278 (50), 247 (100), 219 (50), 189 (40), 165 (30). HR-MS (ESI)  $m/z$  calcd for  $\text{C}_{19}\text{H}_{18}\text{O}_4$  [ $\text{M}+\text{H}^+$ ] 310.1205, found 310.1214.



### Methyl 3',4',5'-trimethoxy-3-methyl-[1,1'-biphenyl]-2-carboxylate (**3an**)

The general procedure **GP1** was followed using benzoic acid **1a** (68 mg, 0.50 mmol) and aryl bromide **2n** (185 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3an** (133 mg, 84%) as a colorless oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta = 7.35$ – $7.30$  (m, 1H), 7.25–7.16 (m, 2H), 6.57 (s, 2H), 3.86 (s, 3H), 3.84 (s, 6H), 3.62 (s, 3H), 2.36 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta = 170.4$  ( $\text{C}_q$ ), 153.0 ( $\text{C}_q$ ), 139.9 ( $\text{C}_q$ ), 137.3 ( $\text{C}_q$ ), 136.4 ( $\text{C}_q$ ), 135.3 ( $\text{C}_q$ ), 133.1 ( $\text{C}_q$ ), 129.3 (CH), 129.1 (CH), 126.9 (CH), 105.4 (CH), 60.9 ( $\text{CH}_3$ ), 56.0 ( $\text{CH}_3$ ), 52.0 ( $\text{CH}_3$ ), 19.6 ( $\text{CH}_3$ ). IR (ATR): 2942, 2836, 1723, 1577, 1462, 1405, 1120  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity) 316 (100) [ $\text{M}^+$ ], 301 (80), 285 (10), 273 (15), 241 (10), 209 (10), 199 (10). HR-MS (EI)  $m/z$  calcd for  $\text{C}_{18}\text{H}_{20}\text{O}_5$  [ $\text{M}+\text{H}^+$ ] 316.1311, found 316.1301.


The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>



### Methyl 4-methoxy-[1,1':3',1''-terphenyl]-2'-carboxylate (**3ba**)

The general procedure **GP1** was followed using benzoic acid **1b** (99 mg, 0.50 mmol) and aryl bromide **2a** (140 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ba** (140 mg, 88%) as a colorless solid. M. p. = 90–91 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.52 (dd,  $J$  = 7.5, 7.5 Hz, 1H), 7.47–7.42 (m, 4H), 7.42–7.35 (m, 5H), 6.99 (d,  $J$  = 8.6 Hz, 2H), 3.86 (s, 3H), 3.45 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  = 170.1 ( $\text{C}_q$ ), 159.2 ( $\text{C}_q$ ), 140.6 ( $\text{C}_q$ ), 140.3 ( $\text{C}_q$ ), 140.0 ( $\text{C}_q$ ), 132.9 ( $\text{C}_q$ ), 132.9 ( $\text{C}_q$ ), 129.6 (CH), 129.4 (CH), 128.9 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 127.6 (CH), 113.9 (CH), 55.3 ( $\text{CH}_3$ ), 51.8 ( $\text{CH}_3$ ). IR (ATR): 2947, 2834, 1727, 1584, 1453, 1249, 1116, 1029, 763  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity): 318 (97) [ $\text{M}^+$ ], 287 (100), 255 (12), 215 (35), 189 (13). HR-MS (EI):  $m/z$  calcd for  $\text{C}_{21}\text{H}_{18}\text{O}_3$  [ $\text{M}^+$ ] 318.1256, found 318.1256.

The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>




### Methyl 3,4'-dimethoxy-[1,1'-biphenyl]-2-carboxylate (**3ca**)

The general procedure **GP1** was followed using benzoic acid **1c** (76 mg, 0.50 mmol) and aryl bromide **2a** (140 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ca** (79 mg, 58%) as a colorless solid. M. p. = 92–93 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.43–7.29 (m, 3H), 6.99–6.88 (m, 4H), 3.87 (s, 3H), 3.83 (s, 3H), 3.66 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  = 168.7 ( $\text{C}_q$ ), 159.2 ( $\text{C}_q$ ), 156.4 ( $\text{C}_q$ ), 140.8 ( $\text{C}_q$ ), 132.4 ( $\text{C}_q$ ), 130.4 (CH), 129.3 (CH), 123.0 ( $\text{C}_q$ ), 121.9 (CH), 113.8 (CH), 109.5 (CH), 56.0 ( $\text{CH}_3$ ), 55.2 ( $\text{CH}_3$ ), 52.1 ( $\text{CH}_3$ ). IR (ATR): 2959, 2860, 1726, 1464, 1238, 1102, 1018,

791  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity) 272 (90) [ $\text{M}^+$ ], 241 (100), 226 (40), 211 (15), 198 (20), 183 (15), 168 (10). HR-MS (EI)  $m/z$  calcd for  $\text{C}_{16}\text{H}_{16}\text{O}_4$  [ $\text{M}^+$ ] 272.1049, found 272.1045.

The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>



The general procedure **GP1** was followed using benzoic acid **1d** (61 mg, 0.50 mmol), 1-iodo-4-methoxybenzene **2a'** (351 mg, 1.50 mmol, 3.0 equiv) and  $\text{K}_2\text{CO}_3$  (276 mg, 2.00 mmol, 4.0 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3da** (143 mg, 82%) and the diarylated product **3da'** (19 mg, 16%).

#### Methyl 4,4''-dimethoxy-[1,1':3,1''-terphenyl]-2'-carboxylate (**3da**)

Colorless solid. M. p. = 112–113 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.47 (dd,  $J$  = 8.2, 7.1 Hz, 1H), 7.39–7.30 (m, 6H), 6.95 (d,  $J$  = 8.9 Hz, 4H), 3.85 (s, 6H), 3.45 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  = 170.2 ( $\text{C}_q$ ), 159.1 ( $\text{C}_q$ ), 139.8 ( $\text{C}_q$ ), 132.9 ( $\text{C}_q$ ), 132.7 ( $\text{C}_q$ ), 129.5 (CH), 129.2 (CH), 128.5 (CH), 113.7 (CH), 55.2 ( $\text{CH}_3$ ), 51.8 ( $\text{CH}_3$ ). IR (ATR): 2920, 2835, 1730, 1586, 1513, 1246, 1103, 1027  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity) 348 (100) [ $\text{M}^+$ ], 317 (90), 302 (10), 285 (10), 274 (20), 259 (10), 202 (20). HR-MS (EI)  $m/z$  calcd for  $\text{C}_{22}\text{H}_{20}\text{O}_4$  [ $\text{M}^+$ ] 348.1362, found 348.1368.


The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>

#### Methyl 4'-methoxy-[1,1'-biphenyl]-2-carboxylate (**3da'**)

Colorless oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.80–7.73 (m, 1H), 7.55–7.43 (m, 1H), 7.38–7.33 (m, 2H), 7.23 (d,  $J$  = 8.8 Hz, 2H), 6.92 (d,  $J$  = 8.8 Hz, 2H), 3.83 (s, 3H), 3.65 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  = 169.4 ( $\text{C}_q$ ), 158.9 ( $\text{C}_q$ ), 142.0 ( $\text{C}_q$ ), 133.6 ( $\text{C}_q$ ), 131.2 (CH), 130.8

(C<sub>q</sub>), 130.7 (CH), 129.7 (CH), 129.4 (CH), 126.8 (CH), 113.5 (CH), 55.2 (CH<sub>3</sub>), 51.9 (CH<sub>3</sub>). IR (ATR): 2949, 2836, 1716, 1610, 1516, 1238, 761 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 242 (95) [M<sup>+</sup>], 211 (100), 196 (10), 183 (15), 168 (30), 139 (40). HR-MS (EI) *m/z* calcd for C<sub>15</sub>H<sub>14</sub>O<sub>3</sub> [M<sup>+</sup>] 242.0943, found 242.0946.

The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>



The general procedure **GP1** was followed using benzoic acid **1e** (95 mg, 0.50 mmol), 1-iodo-4-methoxybenzene **2a'** (351 mg, 1.50 mmol, 3.0 equiv) and K<sub>2</sub>CO<sub>3</sub> (276 mg, 2.00 mmol, 4.0 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 10:1) yielded **3ea** (108 mg, 52%) and the diarylated product **3ea'** (39 mg, 25%).


#### Methyl 4,4'-dimethoxy-5-(trifluoromethyl)-[1,1':3',1''-terphenyl]-2'-carboxylate (**3ea**)

Colorless solid. M. p. = 133–134 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 7.56 (d, *J* = 0.7 Hz, 2H), 7.33 (d, *J* = 8.9 Hz, 4H), 6.94 (d, *J* = 8.9 Hz, 4H), 3.83 (s, 6H), 3.44 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ = 169.1 (C<sub>q</sub>), 159.6 (C<sub>q</sub>), 140.8 (C<sub>q</sub>), 135.9 (q, <sup>4</sup>*J*<sub>C-F</sub> = 1.1 Hz, C<sub>q</sub>), 131.3 (q, <sup>2</sup>*J*<sub>C-F</sub> = 32.6 Hz, C<sub>q</sub>), 131.5 (C<sub>q</sub>), 129.5 (CH), 125.1 (q, <sup>3</sup>*J*<sub>C-F</sub> = 3.7 Hz, CH), 123.7 (q, <sup>1</sup>*J*<sub>C-F</sub> = 272.9 Hz, C<sub>q</sub>), 114.0 (CH), 55.3 (CH<sub>3</sub>), 52.1 (CH<sub>3</sub>). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ = -62.79 (s). IR (ATR): 2943, 2841, 1735, 1609, 1517, 1363, 1120, 809 cm<sup>-1</sup>. MS (ESI) *m/z* 439 [M+Na<sup>+</sup>]. HR-MS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>O<sub>4</sub> [M+H<sup>+</sup>] 417.1308, found 417.1316.

#### Methyl 4'-methoxy-5-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylate (**3ea'**)

Colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 7.85 (dd, *J* = 8.6, 0.9 Hz, 1H), 7.64–7.57 (m, 2H), 7.24 (d, *J* = 8.9 Hz, 2H), 6.94 (d, *J* = 8.9 Hz, 2H), 3.84 (s, 3H), 3.68 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ = 168.4 (C<sub>q</sub>), 159.5 (C<sub>q</sub>), 142.5 (C<sub>q</sub>), 134.2 (q, <sup>4</sup>*J*<sub>C-F</sub> = 1.0 Hz, C<sub>q</sub>), 132.8


(q,  $^2J_{C-F} = 32.6$  Hz, C<sub>q</sub>), 132.0 (C<sub>q</sub>), 130.1 (CH), 129.4 (CH), 127.4 (q,  $^3J_{C-F} = 3.7$  Hz, CH), 123.6 (q,  $^4J_{C-F} = 272.9$  Hz, C<sub>q</sub>), 123.5 (q,  $^3J_{C-F} = 3.8$  Hz, CH), 113.8 (CH), 55.3 (CH<sub>3</sub>), 52.3 (CH<sub>3</sub>).  $^{19}\text{F}$  NMR (376 MHz, CDCl<sub>3</sub>)  $\delta = -63.00$  (s). IR (ATR): 2953, 2840, 1724, 1610, 1518, 1244, 1125, 833 cm<sup>-1</sup>. MS (ESI)  $m/z$  333 [M+Na<sup>+</sup>]. HR-MS (ESI)  $m/z$  calcd for C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>O<sub>3</sub> [M+H<sup>+</sup>] 311.0890, found 311.0899.



### Methyl 2-(4-methoxyphenyl)-1-naphthoate (**3fa**)

The general procedure **GP1** was followed using benzoic acid **1f** (86 mg, 0.50 mmol) and aryl bromide **2a** (140 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3fa** (114 mg, 78%) as a colorless solid. M. p. = 121–122 °C.  $^1\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta = 7.99$ – $7.85$  (m, 3H), 7.63–7.48 (m, 3H), 7.43 (d,  $J = 8.8$  Hz, 2H), 6.99 (d,  $J = 8.8$  Hz, 2H), 3.87 (s, 3H), 3.76 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz, CDCl<sub>3</sub>)  $\delta = 170.2$  (C<sub>q</sub>), 159.2 (C<sub>q</sub>), 137.5 (C<sub>q</sub>), 133.2 (C<sub>q</sub>), 132.1 (C<sub>q</sub>), 130.0 (C<sub>q</sub>), 129.8 (CH), 129.7 (C<sub>q</sub>), 129.6 (CH), 128.1 (CH), 127.5 (CH), 127.4 (CH), 126.1 (CH), 124.9 (CH), 113.9 (CH), 55.3 (CH<sub>3</sub>), 52.2 (CH<sub>3</sub>). IR (ATR): 2937, 1727, 1608, 1516, 1231, 1025, 815 cm<sup>-1</sup>. MS (EI)  $m/z$  (relative intensity) 292 (98) [M<sup>+</sup>], 261 (100), 246 (10), 218 (20), 189 (30), 163 (5), 146 (5). HR-MS (EI)  $m/z$  calcd for C<sub>19</sub>H<sub>16</sub>O<sub>3</sub> [M<sup>+</sup>] 292.1099, found 292.1090.


The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>



### Methyl 4'-methoxy-4,5-dimethyl-[1,1'-biphenyl]-2-carboxylate (**3ga**)

The general procedure **GP1** was followed using benzoic acid **1g** (75 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (**2a'**) (175 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ga** (112 mg, 83%) as a colorless solid. M. p. = 82–83 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 7.62 (s, 1H), 7.23 (d, *J* = 8.8 Hz, 2H), 7.13 (s, 1H), 6.93 (d, *J* = 8.8 Hz, 2H), 3.85 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H), 2.32 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ = 169.2 (C<sub>q</sub>), 158.7 (C<sub>q</sub>), 140.3 (C<sub>q</sub>), 139.8 (C<sub>q</sub>), 135.2 (C<sub>q</sub>), 133.8 (C<sub>q</sub>), 132.1 (CH), 131.0 (CH), 129.4 (CH), 127.8 (C<sub>q</sub>), 113.3 (CH), 55.2 (CH<sub>3</sub>), 51.7 (CH<sub>3</sub>), 19.7 (CH<sub>3</sub>), 19.2 (CH<sub>3</sub>). IR (ATR): 2951, 1724, 1607, 1488, 1443, 1241, 1026, 834 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 270 (100) [M<sup>+</sup>], 239 (90), 224 (15), 211 (15), 196 (30), 181 (15), 165 (15). HR-MS (EI) *m/z* calcd for C<sub>17</sub>H<sub>18</sub>O<sub>3</sub> [M<sup>+</sup>] 270.1256, found 270.1247.


The analytical data are in accordance with those previously reported in the literature.<sup>[7]</sup>



### Methyl 4'-methoxy-4-methyl-[1,1'-biphenyl]-2-carboxylate (**3ha**)

The general procedure **GP1** was followed using benzoic acid **1h** (68 mg, 0.50 mmol) and aryl bromide **2a** (140 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ha** (86 mg, 67%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.50 (dd, *J* = 1.3, 0.6 Hz, 1H), 7.29–7.04 (m, 4H), 6.82 (d, *J* = 8.7 Hz, 2H), 3.73 (s, 3H), 3.56 (s, 3H), 2.30 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 169.4 (C<sub>q</sub>), 158.8 (C<sub>q</sub>), 139.1 (C<sub>q</sub>), 136.5 (C<sub>q</sub>), 133.5 (C<sub>q</sub>), 131.8 (CH), 130.6 (C<sub>q</sub>), 130.5 (CH), 130.1 (CH), 129.4 (CH), 113.4 (CH), 55.1 (CH<sub>3</sub>), 51.8 (CH<sub>3</sub>), 20.8 (CH<sub>3</sub>). IR (ATR): 2948, 2836, 1715, 1609, 1488, 1289, 1238, 821 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 256 (100) [M<sup>+</sup>], 225 (80), 210 (10), 197 (15), 182 (20), 165 (15), 153 (20). HR-MS (EI) *m/z* calcd for C<sub>16</sub>H<sub>16</sub>O<sub>3</sub> [M<sup>+</sup>] 256.1099, found 256.1091.

The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>



The general procedure **GP1** was followed using benzoic acid **1i** (70 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (**2a'**) (175 mg, 0.75 mmol, 1.5 equiv) and K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.00 mmol, 2.0 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ia** (73 mg, 56%) and the diarylated product **3ia'** (16 mg, 9%).


#### Methyl 4-fluoro-4'-methoxy-[1,1'-biphenyl]-2-carboxylate (**3ia**)

Colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 7.51 (dd, *J* = 9.0, 2.7 Hz, 1H), 7.32 (dd, *J* = 8.5, 5.5 Hz, 1H), 7.24–7.17 (m, 3H), 6.93 (d, *J* = 8.8 Hz, 2H), 3.85 (s, 3H), 3.68 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ = 167.9 (d, <sup>4</sup>*J*<sub>C-F</sub> = 2.4 Hz, C<sub>q</sub>), 161.3 (d, <sup>1</sup>*J*<sub>C-F</sub> = 247.3 Hz, C<sub>q</sub>), 159.0 (C<sub>q</sub>), 138.2 (d, <sup>4</sup>*J*<sub>C-F</sub> = 3.4 Hz, C<sub>q</sub>), 132.6 (C<sub>q</sub>), 132.4 (d, <sup>3</sup>*J*<sub>C-F</sub> = 7.6 Hz, CH), 132.2 (d, <sup>3</sup>*J*<sub>C-F</sub> = 7.3 Hz, C<sub>q</sub>), 129.4 (CH), 118.1 (d, <sup>2</sup>*J*<sub>C-F</sub> = 21.1 Hz, CH), 116.5 (d, <sup>2</sup>*J*<sub>C-F</sub> = 23.4 Hz, CH), 113.5 (CH), 55.2 (CH<sub>3</sub>), 52.1 (CH<sub>3</sub>). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ = -(115.28–115.37) (m). IR (ATR): 2951, 2837, 1718, 1608, 1484, 1235, 1175, 822 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 261 (30) [M+H<sup>+</sup>], 260 [M<sup>+</sup>] (100), 245 (10), 229 (80), 214 (15), 186 (30). HR-MS (EI) *m/z* calcd for C<sub>15</sub>H<sub>13</sub>FO<sub>3</sub> [M<sup>+</sup>] 260.0849, found 260.0857.

#### Methyl 4'-fluoro-4,4''-dimethoxy-[1,1':3,1''-terphenyl]-2'-carboxylate (**3ia'**)

Pale yellow solid. M. p. = 121–122 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.34–7.27 (m, 5H), 7.23–7.20 (m, 1H), 6.96–6.92 (m, 4H), 3.84 (s, 3H), 3.84 (s, 3H), 3.39 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ = 168.7 (d, <sup>4</sup>*J*<sub>C-F</sub> = 3.3 Hz, C<sub>q</sub>), 158.7 (d, <sup>1</sup>*J*<sub>C-F</sub> = 246.1 Hz, C<sub>q</sub>), 159.4 (C<sub>q</sub>), 159.1 (C<sub>q</sub>), 135.7 (d, <sup>3</sup>*J*<sub>C-F</sub> = 4.1 Hz, C<sub>q</sub>), 135.3 (d, <sup>3</sup>*J*<sub>C-F</sub> = 2.7 Hz, C<sub>q</sub>), 132.0 (C<sub>q</sub>), 130.6 (d, <sup>4</sup>*J*<sub>C-F</sub> = 1.4 Hz, CH), 130.2 (d, <sup>3</sup>*J*<sub>C-F</sub> = 8.2 Hz, CH), 129.5 (CH), 127.3 (d, <sup>2</sup>*J*<sub>C-F</sub> = 18.1 Hz, C<sub>q</sub>), 125.4 (C<sub>q</sub>), 116.6 (d, <sup>2</sup>*J*<sub>C-F</sub> = 23.2 Hz, CH), 113.8 (CH), 113.7 (CH), 55.2 (CH<sub>3</sub>), 55.2 (CH<sub>3</sub>),


51.9 (CH<sub>3</sub>). <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ = -117.71 (dd, *J* = 9.2, 5.0 Hz). IR (ATR): 2935, 2837, 1728, 1608, 1514, 1463, 1250, 822 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 389 (100) [M+Na<sup>+</sup>], 335 (10), 278 (5), 219 (10), 203 (5), 149 (5). HR-MS (ESI) *m/z* calcd for C<sub>22</sub>H<sub>20</sub>FO<sub>4</sub> [M+H<sup>+</sup>] 367.1340, found 367.1344.



### Methyl 4'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylate (**3ja**)


The general procedure **GP1** was followed using benzoic acid **1j** (95 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (**2a'**) (175 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ja** (140 mg, 90%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.04 (dd, *J* = 1.4, 0.7 Hz, 1H), 7.73 (ddd, *J* = 8.1, 2.0, 0.8 Hz, 1H), 7.47 (d, *J* = 8.1 Hz, 1H), 7.23 (d, *J* = 8.8 Hz, 2H), 6.94 (d, *J* = 8.7 Hz, 2H), 3.84 (s, 3H), 3.69 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 168.0 (C<sub>q</sub>), 159.5 (C<sub>q</sub>), 145.5 (q, <sup>4</sup>*J*<sub>C-F</sub> = 1.6 Hz, C<sub>q</sub>), 132.1 (C<sub>q</sub>), 131.3 (C<sub>q</sub>), 131.3 (CH), 129.4 (CH), 129.1 (q, <sup>2</sup>*J*<sub>C-F</sub> = 33.1 Hz, C<sub>q</sub>), 127.7 (q, <sup>3</sup>*J*<sub>C-F</sub> = 3.6 Hz, CH), 126.8 (q, <sup>3</sup>*J*<sub>C-F</sub> = 3.8 Hz, CH), 123.7 (q, <sup>1</sup>*J*<sub>C-F</sub> = 272.3 Hz, C<sub>q</sub>), 113.8 (CH), 55.2 (CH<sub>3</sub>), 52.3 (CH<sub>3</sub>). <sup>19</sup>F NMR (283 MHz, CDCl<sub>3</sub>) δ = -62.62 (s). IR (ATR): 2952, 2839, 1726, 1609, 1522, 1334, 1240, 1081 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 310 (100) [M<sup>+</sup>], 279 (90), 264 (10), 251 (15), 236 (20), 207 (10), 188 (10). HR-MS (EI) *m/z* calcd for C<sub>16</sub>H<sub>13</sub>F<sub>3</sub>O<sub>3</sub> [M<sup>+</sup>] 310.0817, found 310.0821.

The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>




### Methyl 3,4,4'-trimethoxy-[1,1'-biphenyl]-2-carboxylate (**3ka**)

The general procedure **GPI** was followed using benzoic acid **1k** (91 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (**2a'**) (175 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ka** (141 mg, 93%) as a colorless solid. M. p. = 106–107 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.27 (d, *J* = 8.8 Hz, 2H), 7.04 (d, *J* = 8.5 Hz, 1H), 6.96 (d, *J* = 8.5 Hz, 1H), 6.88 (d, *J* = 8.8 Hz, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 3.80 (s, 3H), 3.67 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 168.2 (C<sub>q</sub>), 158.9 (C<sub>q</sub>), 151.5 (C<sub>q</sub>), 146.0 (C<sub>q</sub>), 132.2 (C<sub>q</sub>), 132.1 (C<sub>q</sub>), 129.2 (CH), 128.7 (C<sub>q</sub>), 125.2 (CH), 113.7 (CH), 113.5 (CH), 61.6 (CH<sub>3</sub>), 56.0 (CH<sub>3</sub>), 55.2 (CH<sub>3</sub>), 52.1 (CH<sub>3</sub>). IR (ATR): 2936, 2841, 1728, 1480, 1249, 1051, 804, 548 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 302 (100) [M<sup>+</sup>], 287 (20), 271 (30), 259 (20), 240 (20), 225 (15), 213 (20). HR-MS (EI) *m/z* calcd for C<sub>17</sub>H<sub>18</sub>O<sub>5</sub> [M<sup>+</sup>] 302.1154, found 302.1146.



### Methyl 4-acetyl-4'-methoxy-[1,1'-biphenyl]-2-carboxylate (**3la**)


The general procedure **GPI** was followed using benzoic acid **1l** (82 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (**2a'**) (175 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3la** (115 mg, 81%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 8.32 (dd, *J* = 1.9, 0.5 Hz, 1H), 8.05 (dd, *J* = 8.1, 1.9 Hz, 1H), 7.44 (dd, *J* = 8.1, 0.5 Hz, 1H), 7.24 (d, *J* = 8.8 Hz, 2H), 6.92 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H), 3.68 (s, 3H), 2.62 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ = 196.8 (C<sub>q</sub>), 168.6 (C<sub>q</sub>), 159.5 (C<sub>q</sub>), 146.3 (C<sub>q</sub>), 135.3 (C<sub>q</sub>), 132.3 (C<sub>q</sub>), 131.1 (C<sub>q</sub>), 131.0 (CH), 130.5 (CH), 129.9 (CH), 129.4 (CH), 113.7 (CH), 55.2 (CH<sub>3</sub>), 52.2 (CH<sub>3</sub>), 26.6 (CH<sub>3</sub>). IR (ATR): 2950, 2837, 1719, 1682, 1602, 1518, 1226, 826 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 284 (90) [M<sup>+</sup>], 269 (100), 253 (20), 241 (10), 226 (20), 211 (15), 195 (10). HR-MS (EI) *m/z* calcd for C<sub>17</sub>H<sub>16</sub>O<sub>4</sub> [M<sup>+</sup>] 284.1049, found 284.1043.



### Methyl 3-benzoyl-4'-methoxy-[1,1'-biphenyl]-2-carboxylate (**3ma**)

The general procedure **GP1** was followed using benzoic acid **1m** (113 mg, 0.50 mmol) and aryl bromide **2a** (140 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3ma** (92 mg, 53%) as a colorless solid. M. p. = 108–109 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 7.91–7.79 (m, 2H), 7.63–7.50 (m, 3H), 7.53–7.42 (m, 3H), 7.31 (d, *J* = 8.8 Hz, 2H), 6.95 (d, *J* = 8.8 Hz, 2H), 3.84 (s, 3H), 3.45 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ = 196.4 (C<sub>q</sub>), 168.9 (C<sub>q</sub>), 159.3 (C<sub>q</sub>), 141.2 (C<sub>q</sub>), 138.5 (C<sub>q</sub>), 136.8 (C<sub>q</sub>), 133.1 (CH), 132.8 (CH), 132.7 (C<sub>q</sub>), 132.1 (C<sub>q</sub>), 130.1 (CH), 129.5 (CH), 129.2 (CH), 128.4 (CH), 127.8 (CH), 113.8 (CH), 55.2 (CH<sub>3</sub>), 52.1 (CH<sub>3</sub>). IR (ATR): 2950, 2841, 1936, 1730, 1606, 1516, 1247, 1050 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 346 (100) [M<sup>+</sup>], 315 (60), 297 (10), 269 (40), 237 (20), 181 (15), 215 (10). HR-MS (EI) *m/z* calcd for C<sub>22</sub>H<sub>18</sub>O<sub>4</sub> [M<sup>+</sup>] 346.1205, found 346.1194.

The analytical data are in accordance with those previously reported in the literature.<sup>[5]</sup>




### Methyl 2-(4-methoxyphenyl)-1-methyl-1H-indole-3-carboxylate (**3na**)

The general procedure **GP1** was followed using benzoic acid **1n** (88 mg, 0.50 mmol) and aryl bromide **2a** (140 mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **3na** (52 mg, 35%) as a brown solid. The yield could be

improved to 67% when using JohnPhos ligand (10 mol %) instead of PCy<sub>3</sub>. M. p. = 153–154 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 8.32–8.19 (m, 1H), 7.45–7.26 (m, 5H), 7.05 (d, *J* = 8.7 Hz, 2H), 3.90 (s, 3H), 3.80 (s, 3H), 3.58 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 165.8 (C<sub>q</sub>), 160.2 (C<sub>q</sub>), 147.1 (C<sub>q</sub>), 136.8 (C<sub>q</sub>), 131.8 (CH), 126.7 (C<sub>q</sub>), 123.4 (C<sub>q</sub>), 122.8 (CH), 122.1 (CH), 122.0 (CH), 113.7 (CH), 109.8 (CH), 104.9 (C<sub>q</sub>), 55.4 (CH<sub>3</sub>), 50.8 (CH<sub>3</sub>), 30.9 (CH<sub>3</sub>). IR (ATR): 3002, 2943, 1696, 1495, 1388, 1169, 1022, 834, 737 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity): 295 (90) [M<sup>+</sup>], 264 (100), 249 (10), 237 (15), 192 (15). HR-MS (EI): *m/z* calcd for C<sub>18</sub>H<sub>17</sub>NO<sub>3</sub> [M<sup>+</sup>] 295.1208, found 295.1204.


The analytical data are in accordance with those previously reported in the literature.<sup>[8]</sup>



### (*Z*)-7-Methyl-3-[(triisopropylsilyl)methylene]isobenzofuran-1(3*H*)-one (11aa)

The general procedure **GP2** was followed using benzoic acid **1a** (68 mg, 0.50 mmol). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **11aa** (97 mg, 61%) as a colorless solid. M. p. = 135–136 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.61–7.49 (m, 2H), 7.36–7.27 (m, 1H), 5.53 (s, 1H), 2.69 (s, 3H), 1.41–1.29 (m, 3H), 1.11 (d, *J* = 7.2 Hz, 18H). <sup>13</sup>C NMR (75MHz, CDCl<sub>3</sub>) δ = 167.6 (C<sub>q</sub>), 156.5 (C<sub>q</sub>), 139.7 (C<sub>q</sub>), 139.1 (C<sub>q</sub>), 133.9 (CH), 131.7 (CH), 122.6 (C<sub>q</sub>), 118.2 (CH), 99.7 (CH), 18.8 (CH<sub>3</sub>), 17.5 (CH<sub>3</sub>) 11.7 (CH). IR (ATR): 2940, 2863, 1762, 1637, 1461, 1255, 974 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 339 (30) [M+Na<sup>+</sup>], 299 (10), 289 (15), 273 (85), 261 (20), 245 (15), 59 (100). HR-MS (ESI) *m/z* calcd for C<sub>19</sub>H<sub>29</sub>O<sub>2</sub>Si [M+H<sup>+</sup>] 317.1931, found 317.1935.

The analytical data are in accordance with those previously reported in the literature.<sup>[9]</sup>




**(Z)-3-[(Triisopropylsilyl)methylene]naphtho[1,2-c]furan-1(3H)-one (11fa)**

The general procedure **GP2** was followed using benzoic acid **1f** (86 mg, 0.50 mmol). Purification by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) yielded **11fa** (88 mg, 50%) as a colorless solid. M. p. = 131–132 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 8.93–8.83 (m, 1H), 8.09 (d, *J* = 8.4 Hz, 1H), 7.92 (d, *J* = 8.2 Hz, 1H), 7.77–7.66 (m, 2H), 7.60 (ddd, *J* = 8.2, 7.0, 1.3 Hz, 1H), 5.71 (s, 1H), 1.38 (dq, *J* = 14.3, 7.4 Hz, 3H), 1.13 (d, *J* = 7.4 Hz, 18H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ = 167.6 (C<sub>q</sub>), 156.8 (C<sub>q</sub>), 139.6 (C<sub>q</sub>), 135.4 (CH), 133.9 (C<sub>q</sub>), 129.2 (CH), 128.6 (C<sub>q</sub>), 128.4 (CH), 127.6 (CH), 124.2 (CH), 119.2 (C<sub>q</sub>), 117.2 (CH), 102.6 (CH), 18.8 (CH<sub>3</sub>), 11.7 (CH). IR (ATR): 2940, 2862, 1755, 1633, 1458, 1111, 963, 751 cm<sup>-1</sup>. MS (ESI) *m/z* 353 [M+H<sup>+</sup>]. HR-MS (ESI) *m/z* calcd for C<sub>22</sub>H<sub>29</sub>O<sub>2</sub>Si [M+H<sup>+</sup>] 353.1931, found 353.1938.

The analytical data are in accordance with those previously reported in the literature.<sup>[9]</sup>

## Ruthenium (II)-Catalyzed C–H Alkynylation




### Methyl (*E*)-2-methyl-6-styrylbenzoate (**9aa**)



A suspension of [Ru(O<sub>2</sub>CMes)<sub>2</sub>(*p*-cymene)] (**4**) (28.1 mg, 10 mol %), PCy<sub>3</sub> (14.0 mg, 10 mol %), K<sub>2</sub>CO<sub>3</sub> (276 mg, 2.00 mmol, 4.0 equiv), benzoic acid **1a** (68 mg, 0.50 mmol) and (*E*)-(2-bromovinyl)benzene (**8a**) (275 mg, 1.50 mmol, 3.0 equiv) in NMP (2.0 mL) was stirred under N<sub>2</sub> for 16 h at 120 °C. At ambient temperature, MeCN (3.0 mL), K<sub>2</sub>CO<sub>3</sub> (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 °C for another 2 h. At ambient temperature, the mixture was diluted with MTBE (120 mL), then washed with H<sub>2</sub>O (20 mL) and brine (20 mL) sequentially. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc 30:1) to yield the methyl ester **9aa** (71 mg, 56%) as a pale yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.57–7.43 (m, 3H), 7.39–7.23 (m, 4H), 7.17–7.00 (m, 3H), 3.95 (s, 3H), 2.34 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ = 170.2 (C<sub>q</sub>), 137.1 (C<sub>q</sub>), 135.2 (C<sub>q</sub>), 135.0 (C<sub>q</sub>), 132.9 (C<sub>q</sub>), 131.3 (CH), 129.5 (CH), 129.2 (CH), 128.6 (CH), 127.9 (CH), 126.7 (CH), 125.6 (CH), 123.0 (CH), 52.1 (CH<sub>3</sub>), 19.7 (CH<sub>3</sub>). IR (ATR): 3026, 2949, 2862, 1721, 1588, 1436, 1265, 1068 cm<sup>-1</sup>. MS (EI) *m/z* (relative intensity) 252 (100) [M<sup>+</sup>], 237 (10), 220 (50), 193 (30), 178 (50), 165 (20). HR-MS (EI) *m/z* calcd for C<sub>17</sub>H<sub>16</sub>O<sub>2</sub> [M<sup>+</sup>] 252.1150, found 252.1148.


The analytical data are in accordance with those previously reported in the literature.<sup>[10]</sup>

## H-D Exchange Experiments




A suspension of 1-bromo-4-methoxybenzene (**2a**) (140 mg, 0.75 mmol), 4-phenylbenzoic acid (**1o**) (99 mg, 0.50 mmol), [Ru(O<sub>2</sub>CMes)<sub>2</sub>(*p*-cymene)] (**4**) (28.1 mg, 10 mol %), PCy<sub>3</sub> (14.0 mg, 10 mol %), K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.00 mmol) in a solvent mixture of NMP (2.0 mL) and CD<sub>3</sub>OD (0.2 mL) was stirred at 120 °C for 16 h in a seal tube under N<sub>2</sub> atmosphere. At ambient temperature, MeCN (3.0 mL), K<sub>2</sub>CO<sub>3</sub> (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 °C for another 2.0 h. At ambient temperature, the mixture was diluted with MTBE (120 mL), then washed with H<sub>2</sub>O (20 mL) and brine (20 mL) sequentially. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) to yield **[D]<sub>n</sub>-1o** (48 mg, 45%) and **[D]<sub>n</sub>-3oa** (14 mg, 9%). The D-incorporation in **[D]<sub>n</sub>-1o** and **[D]<sub>n</sub>-3oa** was estimated by <sup>1</sup>H-NMR spectroscopy.






A suspension of 1-bromo-4-methoxybenzene (**2a**) (140 mg, 0.75 mmol), benzoic acid (**1d**) (61 mg, 0.50 mmol), [Ru(MesCO<sub>2</sub>)<sub>2</sub>(*p*-cymene)] (**4**) (28.1 mg, 10 mol %), PCy<sub>3</sub> (14.0 mg, 10 mol %), K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.00 mmol) in a solvent mixture of NMP (2.0 mL) and CD<sub>3</sub>OD (0.2 mL) was stirred at 120 °C for 16 h in a seal tube under N<sub>2</sub> atmosphere. At ambient temperature, MeCN (3.0 mL), K<sub>2</sub>CO<sub>3</sub> (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 °C for another 2.0 h. At ambient temperature, the mixture was diluted with MTBE (120 mL), then washed with H<sub>2</sub>O (20 mL), and brine (20 mL) sequentially. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc) to yield [D]<sub>n</sub>-**3da** (18 mg, 16%). The D-incorporation in [D]<sub>n</sub>-**3da** was estimated by <sup>1</sup>H-NMR spectroscopy.




## Competition Experiments

Intermolecular competition experiment between benzoic acid **1h** and **1j**




A suspension of 1-bromo-4-methoxybenzene (**2a**) (94 mg, 0.50 mmol), 3-methylbenzoic acid (**1h**) (82 mg, 0.60 mmol), 3-(trifluoromethyl)benzoic (**1j**) (114 mg, 0.60 mmol), [Ru(O<sub>2</sub>CMes)<sub>2</sub>(*p*-cymene)] (28.1 mg, 10 mol %), PCy<sub>3</sub> (14.0 mg, 10 mol %), K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.00 mmol) in NMP (2.0 mL) was stirred under N<sub>2</sub> for 16 h at 120 °C. At ambient temperature, MeCN (3.0 mL), K<sub>2</sub>CO<sub>3</sub> (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 °C for another 2 h. At ambient temperature, the mixture was

diluted with MTBE (120 mL), then washed with H<sub>2</sub>O (20 mL) and brine (20 mL) sequentially. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) to yield the mixture of **3ha** and **3ja** (41 mg). The ratio was calculated based on <sup>1</sup>H-NMR analysis.




Intermolecular Competition Experiment between aryl bromides **2a** and **2e**.



A suspension of 2-methylbenzoic acid (**1a**) (68 mg, 0.50 mmol), 1-bromo-4-methoxybenzene (**2a**) (112 mg, 0.60 mmol), 1-bromo-4-(trifluoromethyl)benzene (**2e**) (135 mg, 0.60 mmol),

[Ru(MesCO<sub>2</sub>)<sub>2</sub>(*p*-cymene)] (**4**) (28.1 mg, 10 mol %), PCy<sub>3</sub> (14.0 mg, 10 mol %), K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.00 mmol) in NMP (2.0 mL) was stirred under N<sub>2</sub> for 16 h at 120 °C. At ambient temperature, MeCN (3.0 mL), K<sub>2</sub>CO<sub>3</sub> (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 °C for another 2.0 h. At ambient temperature, the mixture was diluted with MTBE (120 mL), then washed with H<sub>2</sub>O (20 mL) and brine (20 mL) sequentially. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc) to yield **3ae** (79 mg, 54%) and **3aa** (41 mg, 32%).

Intermolecular Competition Experiment between Benzoic acid **1h** and triazole **5d**.




A suspension of 1-bromo-4-methoxybenzene (**2a**) (94 mg, 0.50 mmol), 3-methylbenzoic acid (**1h**) (82 mg, 0.60 mmol), 4-*n*-pentyl-1-(*m*-tolyl)-1*H*-1,2,3-triazole (**5d**) (138 mg, 0.60 mmol), [Ru(O<sub>2</sub>CMes)<sub>2</sub>(*p*-cymene)] (**4**) (28.1 mg, 10 mol %), PCy<sub>3</sub> (14.0 mg, 10 mol %), K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.00 mmol) in NMP (2.0 mL) was stirred under N<sub>2</sub> for 16 h at 120 °C. At ambient temperature, MeCN (3.0 mL), K<sub>2</sub>CO<sub>3</sub> (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 °C for another 2.0 h. At ambient temperature, the mixture was diluted with MTBE (120 mL), then washed with H<sub>2</sub>O (20 mL) and brine (20 mL) sequentially. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc) to yield **6da** (94 mg, 56%) and **3ha** (5.1 mg, 4%).

#### 1-(4'-Methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-4-pentyl-1*H*-1,2,3-triazole (**6da**)

Colorless oil; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ = 7.41 (s, 1H), 7.36–7.28 (m, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.90 (s, 1H), 6.77 (d, *J* = 8.7 Hz, 2H), 3.75 (s, 3H), 2.60 (t, *J* = 7.5 Hz, 2H), 2.42

(s, 3H), 1.53 (p,  $J = 7.5$  Hz, 2H), 1.34–1.10 (m, 4H), 0.84 (t,  $J = 7.0$  Hz, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta = 159.0$  ( $\text{C}_q$ ), 147.8 ( $\text{C}_q$ ), 138.2 ( $\text{C}_q$ ), 134.9 ( $\text{C}_q$ ), 133.6 ( $\text{C}_q$ ), 130.6 (CH), 130.3 (CH), 129.7 ( $\text{C}_q$ ), 129.5 (CH), 127.0 (CH), 122.9 (CH), 113.9 (CH), 55.1 ( $\text{CH}_3$ ), 31.0 ( $\text{CH}_2$ ), 28.9 ( $\text{CH}_2$ ), 25.2 ( $\text{CH}_2$ ), 22.3 ( $\text{CH}_2$ ), 20.8 ( $\text{CH}_3$ ), 13.8 ( $\text{CH}_3$ ). IR (ATR): 2927, 2837, 1609, 1638, 1493, 1464, 1245, 1018  $\text{cm}^{-1}$ . MS (EI)  $m/z$  (relative intensity) 335 (10) [ $\text{M}^+$ ], 306 (60), 292 (30), 278 (30), 264 (30), 250 (100), 237 (30). HR-MS (EI)  $m/z$  calcd for  $\text{C}_{21}\text{H}_{25}\text{N}_3\text{O}$  [ $\text{M}^+$ ] 335.1998, found 335.1991.

### C–H Arylations with Ruthenacycle **7**







A suspension of 1-naphthoic acid (**1f**) (0.50 mmol, 86 mg), 1-bromo-4-methoxybenzene (**2a**) (140 mg, 0.75 mmol), ruthenacycle **7** (24.2 mg, 10 mol %),  $\text{PCy}_3$  (14.0 mg, 10 mol %),  $\text{K}_2\text{CO}_3$  (138 mg, 1.00 mmol) in NMP (2.0 mL) was stirred under  $\text{N}_2$  for 16 h at 120 °C. At ambient temperature, MeCN (3.0 mL),  $\text{K}_2\text{CO}_3$  (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 °C for another 2.0 h. At ambient temperature, the mixture was diluted with MTBE (120 mL) then washed with  $\text{H}_2\text{O}$  (20 mL) and brine (20 mL) sequentially. The organic phase was dried over  $\text{Na}_2\text{SO}_4$ , and concentrated *in vacuo*. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc 20:1) to yield **3fa** (95 mg, 54%, based on 0.60 mmol) and starting material methyl 1-naphthoate (31 mg, 28%).





## References





- [1] L. Ackermann, R. Vicente, H. K. Potukuchi, V. Pirovano, *Org. Lett.* **2010**, *12*, 5032–5035.
- [2] A. Demonceau, A. W. Stumpf, E. Saive, A. F. Noels, *Macromolecules* **1997**, *30*, 3127–3136.
- [3] D. Zell, S. Warratz, D. Gelman, S. J. Garden, L. Ackermann, *Chem. Eur. J.* **2016**, *22*, 1248–1252.
- [4] S. Warratz, C. Kornhaaß, A. Cajaraville, B. Niepötter, D. Stalke, L. Ackermann, *Angew. Chem. Int. Ed.* **2015**, *54*, 5513–5517.
- [5] L. Huang, D. Hackenberger, L. J. Gooßen, *Angew. Chem. Int. Ed.* **2015**, *54*, 12607–12611.
- [6] D.-H. Wang, T.-S. Mei, J.-Q. Yu, *J. Am. Chem. Soc.* **2008**, *130*, 17676–17677.
- [7] F. Pünner, J. Schieven, G. Hilt, *Org. Lett.* **2013**, *15*, 4888–4891.
- [8] M. Miyasaka, A. Fukushima, T. Satoh, K. Hirano, M. Miura, *Chem. Eur. J.* **2009**, *15*, 3674–3677.
- [9] Y. Liu, Y. Yang, Y. Shi, X. Wang, L. Zhang, Y. Cheng, J. You, *Organometallics* **2016**, *35*, 1350–1353.
- [10] S. Mochida, K. Hirano, T. Satoh, M. Miura, *J. Org. Chem.* **2011**, *76*, 3024–3033.



# NMR Spectra






























































**3ba**  
(CDCl<sub>3</sub>, 300 MHz)



**3ba**  
(CDCl<sub>3</sub>, 75 MHz)

